We have three newly approved meds for dementia. Brexpiprazole (Rexulti) for agitation, and donanemab (Kisunla) and lecanemab (Leqembi) for the core features of Alzheimer’s. Dr. Collier explains why none of these are first-line.
Zuranolone (Zurzuvae) may be FDA-approved for postpartum depression, but we need a very different medication approach for the 1-2 in 1,000 who develop postpartum psychosis.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.